Ioline D Henter1, Rafael Teixeira de Sousa, Carlos A Zarate. 1. From the Experimental Therapeutics and Pathophysiology Branch, Intramural Research Program, National Institute of Mental Health, National Institutes of Health, Bethesda, MD.
Abstract
LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions in depressive symptoms have been noted in response to subanesthetic doses of the glutamatergic modulator ketamine in subjects with major depressive disorder or bipolar depression. These results have prompted the repurposing or development of other glutamatergic modulators, both as monotherapy or adjunctive to other therapies. Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]).
LEARNING OBJECTIVE: After participating in this activity, learners should be better able to evaluate the evidence supporting the antidepressant effects of glutamatergic modulators.Both preclinical and clinical studies have implicated glutamatergic system dysfunction in the pathophysiology of mood disorders such as bipolar depression and major depressive disorder. In particular, rapid reductions in depressive symptoms have been noted in response to subanesthetic doses of the glutamatergic modulator ketamine in subjects with major depressive disorder or bipolar depression. These results have prompted the repurposing or development of other glutamatergic modulators, both as monotherapy or adjunctive to other therapies. Here, we highlight the evidence supporting the antidepressant effects of various glutamatergic modulators, including (1) broad glutamatergic modulators (ketamine, esketamine, dextromethorphan, dextromethorphan-quinidine [Nuedexta], AVP-786, nitrous oxide [N2O], AZD6765), (2) subunit (NR2B)-specific N-methyl-D-aspartate (NMDA) receptor antagonists (CP-101,606/traxoprodil, MK-0657 [CERC-301]), (3) glycine-site partial agonists (D-cycloserine, GLYX-13, sarcosine, AV-101), and (4) metabotropic glutamate receptor modulators (AZD2066, RO4917523/basimglurant, JNJ40411813/ADX71149, R04995819 [RG1578]).
Authors: Madhukar H Trivedi; A John Rush; Stephen R Wisniewski; Andrew A Nierenberg; Diane Warden; Louise Ritz; Grayson Norquist; Robert H Howland; Barry Lebowitz; Patrick J McGrath; Kathy Shores-Wilson; Melanie M Biggs; G K Balasubramani; Maurizio Fava Journal: Am J Psychiatry Date: 2006-01 Impact factor: 18.112
Authors: F G Salituro; R C Tomlinson; B M Baron; M G Palfreyman; I A McDonald; W Schmidt; H Q Wu; P Guidetti; R Schwarcz Journal: J Med Chem Date: 1994-02-04 Impact factor: 7.446
Authors: Marije aan het Rot; Katherine A Collins; James W Murrough; Andrew M Perez; David L Reich; Dennis S Charney; Sanjay J Mathew Journal: Biol Psychiatry Date: 2010-01-15 Impact factor: 13.382
Authors: Sheldon H Preskorn; Bryan Baker; Sheela Kolluri; Frank S Menniti; Michael Krams; Jaren W Landen Journal: J Clin Psychopharmacol Date: 2008-12 Impact factor: 3.153
Authors: Christoph Kraus; Daniel Wasserman; Ioline D Henter; Elia Acevedo-Diaz; Bashkim Kadriu; Carlos A Zarate Journal: Drug Discov Today Date: 2019-08-02 Impact factor: 7.851
Authors: Cristan A Farmer; Jessica R Gilbert; Ruin Moaddel; Jomy George; Lilian Adeojo; Jacqueline Lovett; Allison C Nugent; Bashkim Kadriu; Peixiong Yuan; Todd D Gould; Lawrence T Park; Carlos A Zarate Journal: Neuropsychopharmacology Date: 2020-04-06 Impact factor: 7.853